| abstract |
The invention relates to compounds having formula (I), which are characterised in that: X denotes oxygen or sulphur; Y denotes oxygen, -NH or -N(C1-C6)alkyl; Ra denotes hydrogen, halogen, (C1-C3)alkyl, hydroxy, or (C1-C3)alkoxy; Rb denotes hydrogen, halogen, or (C1-C3)alkyl; A denotes phenyl, pyridyl, (C5-C6)cycloalkyl or (C5-C6)cycloalkenyl; R1 and R2 each denote a group selected from hydrogen, halogen, cyano, nitro, halogenoalkyl, halogenoalkoxy, alkyl, alkenyl, alkynyl, -OR4, -NR4R5, -S(O)nR4, -C(O)R4, -C02R4, -O-C(O)R4, -C(O)NR4R5, -NR5-C(O)R4, -NR5-S02R4, -T-CN, -T-OR4, -T-OCF3, -T-NR4R5, -T-S(O)nR4, -T-C(O)R4, -T-C02R4, -T-O-C(O)R4, -T-C(O)NR4R5, -T-NR4-C(O)R5, -T-NR4-S02R5, -R6, and -T-R6, wherein n, T, R4, R5 and R6 are as defined in the description; and R3 denotes a -R7 or -U-R11 group, wherein R7 denotes hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U denotes a linear or branched alkylene chain and R11 is as defined in the description. The invention also relates to the optical isomers thereof or the addition salts of same having a pharmaceutically-acceptable base or acid. The invention further relates to the use of said compounds as an inhibitor of metalloproteinase and, more specifically, of metalloproteinase-12. |